Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Codexis is a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover and develop novel, high performance enzymes for three healthcare industry pillars: pharmaceutical manufacturing, life sciences, and biotherapeutic discovery & development. The enzymes we produce aim to solve real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and - as biotherapeutic candidates - they have the potential to treat challenging diseases. To meet this goal, we look for individuals who are driven, eager to grow and ready to embrace meaningful challenges. We empower employees to be authentic, ambitious, agile and have the courage to take action where they can make a positive impact. Whether you are driven by science, or a different area of expertise, we need you to help us create a brighter future.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
76 articles about Codexis, Inc.
-
Codexis Reports First Quarter 2023 Financial Results
5/4/2023
Codexis, Inc., a leading enzyme engineering company, announced financial results for the first quarter ended March 31, 2023, and provided a business update.
-
Codexis to Report First Quarter 2023 Financial Results on May 4
4/20/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market.
-
Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA
4/19/2023
Codexis, Inc. announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annual meeting being held May 7-10, 2023, in San Diego, CA.
-
Codexis Announces New Employment Inducement Grants - April 06, 2023
4/6/2023
Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors.
-
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
4/4/2023
Codexis, Inc., a leading enzyme engineering company, announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors.
-
Codexis Announces New Employment Inducement Grants - March 09, 2023
3/9/2023
Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors.
-
Codexis to Participate in Cowen 43rd Annual Health Care Conference
2/27/2023
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts.
-
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
2/23/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.
-
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
2/23/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, and Nestlé Health Science, a leader in the science of nutrition, today announced interim results from a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108.
-
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
2/22/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19th Annual WORLDSymposium™, taking place from February 22-26, 2023, in Orlando, Florida.
-
Codexis Announces New Employment Inducement Grants - February 15, 2023
2/15/2023
Codexis, Inc., a leading enzyme engineering company, announced the grant of an inducement award to the Company’s recently appointed Chief Financial Officer, Sri Ryali.
-
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
2/9/2023
Codexis, Inc., a leading enzyme engineering company, announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market.
-
Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
1/23/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately.
-
Codexis Announces Appointment of H. Stewart Parker to Board of Directors
12/20/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors.
-
Codexis Provides Update on Prioritized Corporate Strategy
11/29/2022
Codexis, Inc., a leading enzyme engineering company, announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success.
-
Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference
11/16/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held on November 29-December 1, 2022, in New York, New York.
-
Codexis to Participate in Upcoming Healthcare Conferences in November 2022
11/8/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming investor conferences.
-
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
-
Codexis Reports Third Quarter 2022 Financial Results
11/3/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
11/1/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel, effective immediately.